<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793910</url>
  </required_header>
  <id_info>
    <org_study_id>WRAMC WU# 08-6960</org_study_id>
    <nct_id>NCT00793910</nct_id>
  </id_info>
  <brief_title>Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy</brief_title>
  <official_title>Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of an oral medication called
      gabapentin in reducing pain after Photorefractive Keratectomy (PRK) eye surgery and to
      assess the frequency of use of rescue medication interventions, defined as non-steroidal
      anti-inflammatory (NSAID) eye drops and oral narcotic medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>day 1 postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>3 days postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>4 days postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of Use of Rescue Medication</measure>
    <time_frame>2 hours to 4 days postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of use of either ketorolac eyedrops(Acular) or oxycodone-acetaminophen tablet (Percocet), or both was measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 300 mg taken by mouth thrice daily for 7 days</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and provide informed consent to participate in this study and
             complete follow-up visits.

          -  Planned Photorefractive keratectomy (PRK) at the WRAMC Center for Refractive Surgery.

          -  Male or female, of any race, and at least 21 years old at the time of the
             pre-operative examination, and have signed an informed consent. The lower age limit
             of 21 years is intended to ensure documentation of refractive stability.

          -  Access to transportation to meet follow-up requirements.

        Exclusion Criteria:

          -  Any reason to be excluded for PRK.

          -  Female subjects who are pregnant, breast feeding or intend to become pregnant during
             the study. Female subjects will be given a urine pregnancy test prior to
             participating in the study to rule out pregnancy. [Pregnancy and breastfeeding are
             contraindications to refractive surgery in general, including PRK, whether
             participating in this study or not].

          -  Patients with known allergy, sensitivity or inappropriate responsiveness to
             Gabapentin or any of the medications used in the post-operative course.

          -  Patients with known depressed renal function.

          -  Any physical or mental impairment that would preclude participation in any of the
             examinations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 10, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2008</firstreceived_date>
  <firstreceived_results_date>November 21, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fort Belvoir Community Hospital</investigator_affiliation>
    <investigator_full_name>Samantha B. Rodgers, MD</investigator_full_name>
    <investigator_title>Assistant Director, Warfighter Refractive Eye Surgery Program and Research Center at Fort Belvoir</investigator_title>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>PRK</keyword>
  <keyword>pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>discarded study pills</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not pick up medications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible based on entry criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>decided to undergo LASIK instead of PRK</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="94"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="94"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.7" spread="8"/>
                <measurement group_id="B2" value="33.2" spread="7.9"/>
                <measurement group_id="B3" value="31.9" spread="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="94"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Pain</title>
        <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
        <time_frame>2 hours postoperatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>11 patients who had alcohol-assisted PRK were removed from data analysis; 1 patient was disenrolled due to nausea secondary to oxycodone-acetaminophen (Percocet) intake</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Level of Pain</title>
            <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.85" spread="2.05"/>
                  <measurement group_id="O2" value="4.09" spread="2.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurence of Use of Rescue Medication</title>
        <description>Occurrence of use of either ketorolac eyedrops(Acular) or oxycodone-acetaminophen tablet (Percocet), or both was measured</description>
        <time_frame>2 hours to 4 days postoperatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>11 patients who had alcohol-assisted PRK were removed from data analysis; 1 patient was disenrolled due to nausea secondary to oxycodone-acetaminophen (Percocet) intake</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Occurence of Use of Rescue Medication</title>
            <description>Occurrence of use of either ketorolac eyedrops(Acular) or oxycodone-acetaminophen tablet (Percocet), or both was measured</description>
            <units># of times rescue meds were used</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.54" spread="3.45"/>
                  <measurement group_id="O2" value="7.15" spread="3.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Level of Pain</title>
        <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
        <time_frame>day 1 postoperatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>11 patients who had alcohol-assisted PRK were removed from data analysis; 1 patient was disenrolled due to nausea secondary to oxycodone-acetaminophen (Percocet) intake</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Level of Pain</title>
            <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.00" spread="2.01"/>
                  <measurement group_id="O2" value="4.00" spread="1.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Level of Pain</title>
        <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
        <time_frame>3 days postoperatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>11 patients who had alcohol-assisted PRK were removed from data analysis; 1 patient was disenrolled due to nausea secondary to oxycodone-acetaminophen (Percocet) intake</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Level of Pain</title>
            <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.09" spread="1.57"/>
                  <measurement group_id="O2" value="2.58" spread="2.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Level of Pain</title>
        <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
        <time_frame>4 days postoperatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>11 patients who had alcohol-assisted PRK were removed from data analysis; 1 patient was disenrolled due to nausea secondary to oxycodone-acetaminophen (Percocet) intake</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Level of Pain</title>
            <description>level of pain was measured using the Visual Analog Scale (VAS)ranging from 0 (none) to 10 (worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.30" spread="1.16"/>
                  <measurement group_id="O2" value="1.86" spread="1.96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Gabapentin 300mg taken by mouth thrice daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo (sugar pill) taken by mouth thrice daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All materials that reflects the WRAMC affiliation must be approved and properly cleared before the material is submitted for public dissemination and publication. All publications whereby WRAMC is cited in the bylines will state on the cover page the following sample disclaimer: “The views expressed in this [article, book chapter, speech, presentation, etc.] are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or U.S. Government.”</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Kuhnle, DO</name_or_title>
      <organization>Carl R. Darnall Army Medical Center</organization>
      <phone>216-965-3518</phone>
      <email>matthew.kuhnle@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
